Identification and Validation of Ecto-5' Nucleotidase as an Immunotherapeutic Target in Multiple Myeloma
ArghyaRay-21-BCJ-0687RR -CD73-manuscript-for-waiver-01-10-22.docx (36.52Kb)
Access StatusFull text of the requested work is not available in DASH at this time ("dark deposit"). For more information on dark deposits, see our FAQ.
MetadataShow full item record
CitationRay, Arghya, Yan Song, Ting Du, Leutz Buon, Yu-Tzu Tai, Dharminder Chauhan, and Kenneth C Anderson. 2022. “Identification and Validation of Ecto-5' Nucleotidase as an Immunotherapeutic Target in Multiple Myeloma.” Blood Cancer Journal (New York) 12 (4): 50.
AbstractInteraction of plasmacytoid dendritic cells (pDCs) with multiple myeloma (MM) cells, T- or NK-effector cells in the bone marrow (BM) microenvironment induces tumor cell growth, as well as inhibits innate and adaptive immune responses. Defining pDC-MM interaction-triggered immunosuppressive mechanism(s) will enable design of interventional therapies to augment anti-MM immunity. In the present study, we show that pDC-MM interactions induce metabolic enzyme Ecto-5’ Nucleotidase/CD73 in both pDCs and MM cells. Gene expression database from MM patients showed that CD73 levels inversely correlates with overall survival. Using our pDC-MM coculture models, we found that blockade of CD73 with anti-CD73 Abs: decreases adenosine levels; activates MM patient pDCs; and triggers cytotoxic T lymphocytes (CTL) activity against autologous patient MM cells. Combination of anti-CD73 Abs and an immune-stimulating agent TLR-7 agonist enhances autologous MM-specific CD8+ CTL activity. Taken together, our preclinical data suggest that the therapeutic targeting of CD73, alone or in combination with TLR-7 agonist, represents a promising novel strategy to restore host anti-MM immunity.
Citable link to this pagehttps://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37373076
- HMS Scholarly Articles